Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Clinical Trial of High Dose CoQ10 in ALS


Clinical Trial of High Dose CoQ10 in ALS




The purpose of this study is to determine the efficacy and preferred dose of CoQ10 in individuals with ALS for a possible future phase III study.

Study Status: Completed


Condition Intervention Phase
Amyotrophic Lateral Sclerosis
Lou Gehrig`s Disease
Drug: coenzyme Q10
Drug: Placebo
Phase 2

Verified by Columbia University February, 2011

Sponsored by: Columbia University
Information provided by: Columbia University identifier: NCT00243932

Study Type: Interventional

Study Design: Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Cleveland Clinic Foundation
Cleveland, Ohio 44101
United States

Petra Kaufmann, MD., Principal Investigator
J. L. P. Thompson, Ph.D.., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site